Quick Answer
Evommune, Inc. reported R&D Expense of $74.04 million for fiscal year 2025.
Evommune, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $74.04M | +15.3% |
| 2024 | $64.24M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $19.64M | +47.8% | +47.8% |
| September 30, 2024 | $13.29M | — | — |
- Evommune, Inc. showed an increase of +15.3% in R&D Expense compared to the prior fiscal year.
- Over the 2024–2025 period, Evommune, Inc.’s r&d expense has grown by 15.3% (from $64.24 million to $74.04 million).
- The most recent figure is from Evommune, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: